A unique vaccine

Mymetics is the global leader in the know-how and research for virosome based vaccines.


A rich and validated

Five vaccine candidates and high value partnerships and collaboration with some of the world’s leading research funding organizations.


Prevention with
innovative science

Developing new generation of vaccines by blocking entry of the virus at the mucosal level, the gateway of human infections.


The world needs
many more vaccines

Only 26 diseases are addressed by vaccines in the world today. Our technology could be a tremendous asset to develop the next-generation prophylactic vaccines for infectious diseases.

About us

More than 30 years of experience in the field of virosome vaccines, a unique R&D expertise, and intellectual property rights, makes Mymetics the global leader in this field. A focused strategy based on a sound scientific approach have resulted in the development a rich pipeline of 5 vaccine candidates...

Read more


Few companies in the world have developed such a powerful technology platform and a unique know-how to develop next-generation prophylactic vaccines for infectious diseases...

Read more



Highly contagious virus and with a high prevalence in developed countries, causing respiratory tract infections in patients of all ages. There is currently no approved RSV vaccine available.


With over 36 million victims, it is the fourth cause of mortality worldwide. Mymetics’ HIV vaccine is the first with a demonstrated ability to prevent viral transmission in primates.


Malaria is an entirely preventable and treatable mosquito-borne illness, but still caused 627,000 deaths in 2012… we are developing a transmission blocking malaria vaccine

Intra-nasal Influenza

Influenza, commonly referred as flu, is a contagious respiratory illness caused by influenza viruses. It rapidly spreads around the world in seasonal epidemics and imposes a considerable economic burden in the form of hospital and other health care costs and lost productivity. In annual influenza epidemics, 5-15% of the population is affected with upper respiratory tract infections.

Herpes Simplex

HSV-1 is common (infecting 40-60% of people) and predominantly induces lip, mouth and facial blisters, or the genitalia. HSV-2 is more usually sexually transmitted and affects the genitalia in about 20% of the population...

Key Partnership

Our virosome vaccine technology and know-how has been validated through high value partnerships and collaboration with some of the world’s leading research funding organizations.

Read more

Media Center

Mymetics Corporation is a US registered biotechnology company with its main office in Switzerland. Mymetics’ vision is to become the market leader in the development of new generation mucosal and virosomes based vaccines. The Company is focused on developing these innovative.

Read more

Social media

Follow Us

Sign UP for our newsletter